10 kids with melanoma tracked for years after drug treatment
NCT ID NCT04196452
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study follows 10 children in the Netherlands who received ipilimumab for advanced melanoma that had spread or could not be removed. Researchers are looking at long-term side effects and patient characteristics. The goal is to understand how safe the drug is over time in young patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ipilimumab
- What this could lead to
- If successful, this study could provide valuable long-term safety data for ipilimumab use in children with advanced melanoma.
- What could go wrong
- This is a small, observational study with only 10 participants, so results may not apply broadly. It does not test a new treatment, only monitors past use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can new drug cocktails reawaken the immune system against melanoma?
- Could a Six-Month exercise and diet plan shield muscle during melanoma treatment?
- Quitting before the knife: which Stop-Smoking aid works best for cancer patients?
- Can a One-Two punch of immune boosters revive cancer treatment?
- Can a modified herpes virus turn the tide against advanced cancer?
- Can your genes predict your melanoma risk?